key: cord-0870022-dv6f9mgt authors: Nie, Lirong; Liu, Yan; Weng, Yijie; Zheng, Yaqiong; Cai, Liping; Kou, Guomei; Xiong, Zhou; Liu, Lei title: Lymphocytes screening on admission is essential for predicting in‐hospital clinical outcome in COVID‐19 patients: A retrospective cohort study date: 2021-06-30 journal: Int J Lab Hematol DOI: 10.1111/ijlh.13640 sha: ae63b799d2848b4d29e2ae2e5d5e95cbd530c486 doc_id: 870022 cord_uid: dv6f9mgt INTRODUCTION: We aimed to identify the associations between the lymphocytes (LYM) absolute count on admission and clinical outcomes in COVID‐19 patients. METHODS: In this retrospective study, 224 COVID‐19 patients who were admitted to General Hospital of Central Theater Command of the PLA from January 22 to April 4, 2020, were consecutively included. These patients were divided into the lymphopenia group and the nonlymphopenia group according to whether the LYM count on admission was below the normal range. RESULTS: During hospitalization, patients in the lymphopenia group have a much higher all‐cause mortality (14.5% vs 0.0%; P < .001) and an evidently longer length of hospital stay (24.0 vs 17.5 days; P < .001) than patients in the nonlymphopenia group. The correlation analysis results indicated that the LYM count was negatively correlated with the values of NEU (R = −.2886, P < .001), PT (R = −.2312, P < .001), FIB (R = −.2954, P < .001), D‐D (R = −.3554, P < .001), CRP (R = −.4899, P < .001), IL‐6 (R = −.5459, P < .001), AST (R = −.2044, P < .01), Cr (R = −.1350, P < .05), CPK (R = −.2119, P < .01), CK‐Mb (R = −.1760, P < .01), and LDH (R = −.4330, P < .001), and was positively correlated with the count of PLT (R = .2679, P < .001). In addition, LYM as a continuous variable was associated with 97% decreased risk of in‐hospital mortality in the fully adjusted models (OR = 0.03, 95%CI, 0.00‐0.37, P < .001). DISCUSSION: LYM screening on admission is a critical predictor for assessment of disease severity and clinical outcomes in patients with COVID‐19, and lymphopenia substantially correlates with poor clinical outcomes. to find the clinical indicators that can reasonably evaluate disease progression and effectively predict clinical outcomes in COVID-19 patients. Many previous studies [1] [2] [3] [4] [5] [6] have showed that lymphopenia often appears in COVID-19 patients especially in severe/critical types and that a potential correlation exists between lymphocytes (LYM) count and disease progression in SARS-CoV-2 infections. Nevertheless, whether LYM screening could be an independent predictor for clinical outcomes (including mortality and length of hospital stay) in hospitalized COVID-19 patients needs to be further elucidated. In the present study, we aimed to clarify the clinical significance of LYM screening and its association with clinical outcomes in COVID-19 patients, which might be helpful for determining the important biomarkers for COVID-19. For this retrospective cohort study, COVID-19 patients who were admitted to General Hospital of Central Theater Command of the PLA from January 22 to April 4, 2020, were consecutively included. The clinical outcomes (discharge from hospital or death) were recorded up to April 4, 2020. All the patients were diagnosed according to WHO interim guidance. As the flow chart ( Figure 1 ) shown, the general information and laboratory data of 356 patients were obtained. Patients who were tested negative for SARS-CoV-2 nucleic acid on admission, being transferred from/to other hospitals during hospitalization, having missing baseline data, or under 18 years old were excluded, and 224 patients were finally included in this research. A patient was categorized as severe case if any of the below clinical scenes additionally appeared: (1) The general information (age, gender, clinical types, signs and symptoms, coexisting disorders, and clinical outcomes) and laboratory find- Continuous variables were described as the means and standard deviations or medians and interquartile ranges (IQR) values. Categorical variables were expressed as the counts and percentages. The clinical characteristics and laboratory data of 224 patients were shown in Table 1 all-cause mortality (14.5% vs 0.0%; P < .001) and an evidently longer length of hospital stay (24.0 vs 17.5 days; P < .001) than patients in the nonlymphopenia group. Moreover, most of the laboratory indicators shown in Table 1 The LYM classification results of 224 patients on admission were shown in Table 2 The results of univariate logistic regression models (Table 3) Figure 2B ) also showed that the length of hospital stay of surviving COVID-19 patients was gradually decreased with the increase in LYM count on admission. Therefore, these results give an idea that lymphopenia on admission is closely related to adverse clinical outcomes. The unadjusted association between baseline variables and all-cause death of 224 COVID-19 patients during hospitalization The results of multivariate logistic regression models assessing the relations of LYM on admission and in-hospital death were shown in Table S1 . In the unadjusted model, LYM was significantly and negatively correlated with the risk of in-hospital death. Adjustment for demographic variables and coexisting disorders (history of hypertension and history of CCD) did not weaken the associations between LYM and in-hospital death (OR = 0.01, 95%CI, 0.00-0.14, P < .001). Further adjusting for the baseline levels of NEU, D-D, CRP, Cr, and LDH also did not affect the relationships in the fully adjusted models. LYM as a continuous variable was associated with 97% decreased risk of in-hospital mortality in the fully adjusted models (OR = 0.03, 95%CI, 0.00-0.37, P < .001). Taken above all, the normal LYM count of COVID-19 patients on admission seems to be a protective factor that can effectively reduce in-hospital mortality. and B cells were also observed in these patients, indicating SARS-CoV-2 infection can also lead to dysregulation in the levels of all LYM subsets. [9] [10] [11] These similar alterations were also found in patients infected by MERS-CoV and SARS-CoV. [12] [13] [14] It has been suggested that lymphopenia might be caused by the exudation of circulating LYM into inflammatory lung tissues, and directly by virus attachment or indirectly by immune injuries from inflammatory mediators. 15 This study illustrates that the LYM count on admission has close associations with disease severity and clinical outcomes in COVID-19 patients and may be a critical biomarker for COVID-19 surveillance. However, multicenter and larger sample size studies are needed to F I G U R E 2 Fitting curve between the LYM count and clinical outcomes in COVID-19 patients. A, The logistic fitting curve was drawn to assess the relation between the LYM count and in-hospital death risk. B, The linear fitting curve was drawn to assess the relation between the LYM count and length of hospital stay. LYM, lymphocytes further explore the relationships between the LYM count and clinical outcomes in COVID-19 patients. The authors have no competing interests. LL and LN conceived the study and designed experimental procedures; YL, YW, YZ, LC, GK, and ZX collected patients' samples. LL and LN wrote the article. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version. The data used to support the findings of this study are available from the corresponding author upon request. https://orcid.org/0000-0001-6764-3260 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan. China Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Biomarkers associated with COVID-19 disease progression A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients Lymphocyte subset counts in COVID-19 patients: a meta-analysis Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages